Net Medical Xpress Solutions Inc
Change company Symbol lookup
Select an option...
NMXS Net Medical Xpress Solutions Inc
ARKG ARK Genomic Revolution ETF
BWA Borgwarner Inc
RCG RENN Global Entrepreneurs Fund, Inc.
SPI SPI Energy Co Ltd
CLH Clean Harbors Inc
CNLMF Collective Mining Ltd
ERIC Telefonaktiebolaget LM Ericsson
DVN Devon Energy Corp
HYZN Hyzon Motors Inc
Go

Health Care : Health Care Technology |
Company profile

Net Medical Xpress Solutions, Inc. provides a range of telemedicine services, including telemedicine software-as-a-service (SaaS), online diagnostic services, virtual specialist services, virtual primary care services and recruitment of telemedicine physicians. The Company operates through four segments: Net Medical Xpress Solutions, Net Medical Xpress Services, Net Medical Xpress Specialists and Net Medical Xpress Staffing. The Net Medical Xpress Solutions segment provides Picture Archiving and Communication System (PACs) hardware and software to hospitals and other medical facilities. The Net Medical Xpress Services provides medical diagnostic reading services. The Net Medical Xpress Specialists provides virtual specialist services to hospitals and other medical entities, and virtual primary care services to individual patients. The Net Medical Xpress Staffing specializes in the recruitment and staffing of physicians for telemedicine services.

Closing Price
$0.06
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
1,177
0

SPPI LOSS ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With LOSSES OVER $100K to Secure Counsel Before Important Deadline in Class Action - SPPI

3:10 pm ET October 8, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / October 8, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) between December 27, 2018 and August 5, 2021, inclusive (the "Class Period"), of the important November 1, 2021 lead plaintiff deadline.

Image: https://www.accesswire.com/users/newswire/images/667437/newlogo.jpg

SO WHAT: If you purchased Spectrum Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spectrum Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facility of ROLONTIS (eflapegrastim), a long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia, maintained deficient controls and/or procedures; (2) the foregoing deficiencies decreased the likelihood that the U.S. Food and Drug Administration ("FDA") would approve the ROLONTIS Biologics License Application (the "ROLONTIS BLA") in its current form; (3) Spectrum Pharmaceuticals had therefore materially overstated the ROLONTIS BLA's approval prospects; and (4) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Spectrum Pharmaceuticals class action, go to http://www.rosenlegal.com/cases-register-2153.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

lrosen@rosenlegal.com

pkim@rosenlegal.com

cases@rosenlegal.com

www.rosenlegal.com

SOURCE: Rosen Law Firm PA

View source version on accesswire.com:

https://www.accesswire.com/667437/SPPI-LOSS-ALERT-ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-Spectrum-Pharmaceuticals-Inc-Investors-With-LOSSES-OVER-100K-to-Secure-Counsel-Before-Important-Deadline-in-Class-Action--SPPI

comtex tracking

COMTEX_394801738/2457/2021-10-08T15:10:34

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.